Showing results (271-280 of 757) with videos related to
Sort By:
Pageof 76
Kidney Medicine|February 29, 2024
Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME TrialSamy Hadjadj, Mark E Cooper, Dominik Steubl, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 6, 2011
Impact of vitamin A on clinical outcomes in haemodialysis patientsKatharina M Espe, Jens Raila, Andrea Henze, et al.Circulation|August 10, 2005
Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout miceSusanne B Schwedler, Kerstin Amann, Konstanze Wernicke, et al.Plos One|January 30, 2014
Increased arterial diameters in the posterior cerebral circulation in men with Fabry diseaseNurcan Uçeyler, György A Homola, Hans Guerrero González, et al.Orphanet Journal of Rare Diseases|August 7, 2013
Fibrosis: a key feature of Fabry disease with potential therapeutic implicationsFrank Weidemann, Maria D Sanchez-Niño, Juan Politei, et al.Diabetes, Obesity & Metabolism|February 11, 2020
Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trialMark E Cooper, Julio Rosenstock, Takashi Kadowaki, et al.Journal of Hypertension|January 14, 2021
Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begunPantelis Sarafidis, Alberto Ortiz, Charles J Ferro, et al.Diabetes, Obesity & Metabolism|February 15, 2022
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomesSabine Kahl, Anne Pernille Ofstad, Bernard Zinman, et al.Molecular Genetics & Genomic Medicine|February 25, 2022
Gene variants of unknown significance in Fabry disease: Clinical characteristics of c.376A>G (p.Ser126Gly)Kolja Lau, Nurcan Üçeyler, Tereza Cairns, et al.Molecular Genetics and Metabolism|May 19, 2023
An expert consensus on the recommendations for the use of biomarkers in Fabry diseaseAlessandro Burlina, Eva Brand, Derralynn Hughes, et al.Pageof 76